|
Thursday, March 4, 2009
LEXINGTON Mass., — March 4, 2010
Inotek Pharmaceuticals Corp., a clinical-stage drug development company advancing innovative drug candidates to address significant diseases of the eye, with a major focus on glaucoma, today announced that Paul G. Howes, President and CEO, will present a corporate overview at the Cowen and Company 30th Annual Health Care Conference on Thursday March 11, 2010 at 9:30 a.m. Eastern Time. The conference will be held at the Boston Marriott Copley Place Hotel, Boston, MA.
About Inotek
Inotek is a privately-held, clinical-stage drug development company advancing innovative drug candidates to address significant diseases of the eye, with a major focus on glaucoma. Inotek's lead drug candidate INO-8875 is a potential first-in-class treatment for glaucoma and ocular hypertension that significantly reduced intraocular pressure (IOP) in glaucoma subjects following single ocular doses in a Phase 1/2 clinical trial. The Company believes INO-8875 will be a breakthrough treatment that can be used alone or combined with other IOP-lowering medicines because it increases the outflow of aqueous humor through the trabecular meshwork, the primary drainage system used by healthy elderly eyes to maintain normal IOP. The Company is also advancing a broad pipeline of PARP inhibitors and SOD mimetics that alleviate oxidative injury and inflammation, which it believes may address significant unmet medical needs in retinal diseases, such as the dry form of age-related macular degeneration (dry AMD). The Company is located in Lexington, MA. For further information on Inotek, please visit www.inotekcorp.com.
Contacts:
Sarah Cavanaugh
MacDougall Biomedical Communications
scavanaugh@macbiocom.com
(781) 235-3060
Adam L. Muzikant, Ph.D.
Senior Director, Business Development
amuzikant@inotekcorp.com
(781) 676-2100
 Download PDF
» Return to InotekCorp.com Press Room
| 
